Mackenzie Financial
PTGX icon

Mackenzie Financial’s Protagonist Therapeutics PTGX Stock Holding History

Mackenzie Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,648
Closed -$318K – 1689
2025
Q4 		$318K Sell
3,648
-416
-10% -$34K ﹤0.01% 1364
2025
Q3 		$270K Sell
4,064
-18,393
-82% -$1.05M ﹤0.01% 1459
2025
Q2 		$1.24M Sell
22,457
-241
-1% -$11.6K ﹤0.01% 957
2025
Q1 		$1.1M Buy
22,698
+1,349
+6% +$56.5K ﹤0.01% 953
2024
Q4 		$824K Buy
21,349
+13,575
+175% +$592K ﹤0.01% 993
2024
Q3 		$350K Buy
+7,774
New +$314K ﹤0.01% 1125
2023
Q3 		– Sell
-12,745
Closed -$284K – 1568
2023
Q2 		$284K Sell
12,745
-14,759
-54% -$369K ﹤0.01% 1184
2023
Q1 		$633K Buy
+27,504
New +$462K ﹤0.01% 958

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Mackenzie Financial's PTGX Position: Q1 2026 in Review

Mackenzie Financial sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 3,648 shares — an estimated $318K sold.

Mackenzie Financial first reported a position in PTGX in Q1 2023 and held it in 8 quarters. The position peaked at $1.24M in Q2 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Mackenzie Financial reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 3,648 Protagonist Therapeutics shares in Q1 2026, an estimated $318K.
  • Mackenzie Financial first reported a position in Protagonist Therapeutics in Q1 2023 and held it in 8 quarters.
  • Mackenzie Financial's Protagonist Therapeutics position peaked at $1.24M in Q2 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.